Rho/rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis

Antioxidants and Redox Signaling

Volumn 20, Issue 8, 2014, Pages 1251-1267

  Sawada, Naoki ^a,b   Liao, James K ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR SYSTEM; CHOLESTEROL; DIABETES MELLITUS; ENZYME ACTIVATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE; PRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84894438924     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5524     Document Type: Review

References (187)

1. This reference has been deleted.
2. This reference has been deleted.
3. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, and Takeshit A. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94: 385-393, 2004.
4. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100: 158-173, 2007.
5. Akiyama N, Naruse K, Kobayashi Y, Nakamura N, Hamada Y, Nakashima E, Matsubara T, Oiso Y, and Nakamura J. High glucose-induced upregulation of Rho/Rho-kinase via platelet-derived growth factor receptorbeta increases migration of aortic smooth muscle cells. J Mol Cell Cardiol 45: 326-332, 2008.
6. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol 62: 10J-15J, 1988.
7. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, and Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl- coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77: 3957-3961, 1980.
8. Alderson LM, Endemann G, Lindsey S, Pronczuk A, Hoover RL, and Hayes KC. LDL enhances monocyte adhesion to endothelial cells in vitro. Am J Pathol 123: 334-342, 1986.
9. Amano M, Chihara K, Nakamura N, Kaneko T, Matsuura Y, and Kaibuchi K. The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J Biol Chem 274: 32418-32424, 1999.
10. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, and Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271: 20246-20249, 1996.
11. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, and Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332: 488-493, 1995.
12. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie E, Otterdal K, Gullestad L, and Damas JK. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 28: 1909-1919, 2008.
13. Bao W, Hu E, Tao L, Boyce R, Mirabile R, Thudium DT, Ma XL, Willette RN, and Yue TL. Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 61: 548-558, 2004.
14. Begum N, Sandu OA, Ito M, Lohmann SM, and Smolenski A. Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J Biol Chem 277: 6214-6222, 2002.
15. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, Lewis RL, Mills TM, Hellstrom WJ, and Kadowitz PJ. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 101: 9121-9126, 2004.
16. Braun-Dullaeus RC, Mann MJ, and Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98: 82-89, 1998.
17. Brown JH, Del Re DP, and Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98: 730-742, 2006.
18. This reference has been deleted.
19. Bryan BA, Mitchell DC, Zhao L, Ma W, Stafford LJ, Teng BB, and Liu M. Modulation of muscle regeneration, myogenesis, and adipogenesis by the Rho family guanine nucleotide exchange factor GEFT. Mol Cell Biol 25: 11089-11101, 2005.
20. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD, Jr., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 323: 946-955, 1990.
21. Burridge K and Wennerberg K. Rho and Rac take center stage. Cell 116: 167-179, 2004.
22. Carter RW, Begaye M, and Kanagy NL. Acute and chronic NOS inhibition enhances alpha(2)-adrenoreceptor-stimulated RhoA and Rho kinase in rat aorta. Am J Physiol Heart Circ Physiol 283: H1361-H1369, 2002.
23. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, and Valente AJ. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB-and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 281: 15099-15109, 2006.
24. Chang J, Xie M, Shah VR, Schneider MD, Entman ML, Wei L, and Schwartz RJ. Activation of Rho-associated coiledcoil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci USA 103: 14495-14500, 2006.
25. Chevrier V, Piel M, Collomb N, Saoudi Y, Frank R, Paintrand M, Narumiya S, Bornens M, and Job D. The Rho-associated protein kinase p160ROCK is required for centrosome positioning. J Cell Biol 157: 807-817, 2002.
26. Chitaley K and Webb RC. Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signaling. Hypertension 39: 438-442, 2002.
27. Chou TC, Yen MH, Li CY, and Ding YA. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 31: 643-648, 1998.
28. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, and Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 3: 339-345, 2001.
29. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, and Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605, 1999.
30. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, and Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885, 1998.
31. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, and Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 83: 683-690, 1998.
32. Eto Y, Shimokawa H, Hiroki J, Morishige K, Kandabashi T, Matsumoto Y, Amano M, Hoshijima M, Kaibuchi K, and Takeshita A. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol Heart Circ Physiol 278: H1744-H1750, 2000.
33. Farah S, Agazie Y, Ohan N, Ngsee JK, and Liu XJ. A rhoassociated protein kinase, ROKalpha, binds insulin receptor substrate-1 and modulates insulin signaling. J Biol Chem 273: 4740-4746, 1998.
34. Feng J, Ito M, Ichikawa K, Isaka N, Nishikawa M, Hartshorne DJ, and Nakano T. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem 274: 37385-37390, 1999.
35. This reference has been deleted.
36. Forstermann U and Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113: 1708-1714, 2006.
37. Fox R, Nhan TQ, Law GL, Morris DR, Liles WC, and Schwartz SM. PSGL-1 and mTOR regulate translation of ROCK-1 and physiological functions of macrophages. EMBO J 26: 505-515, 2007.
38. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, and Shimokawa H. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25: 144-149, 2010.
39. Fukata Y, Oshiro N, Kinoshita N, Kawano Y, Matsuoka Y, Bennett V, Matsuura Y, and Kaibuchi K. Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. J Cell Biol 145: 347-361, 1999.
40. Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Takeda K, Kaibuchi K, Takeya M, Yoshimura T, and Takeshita A. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 38: 100-104, 2001.
41. Furukawa N, Ongusaha P, Jahng WJ, Araki K, Choi CS, Kim HJ, Lee YH, Kaibuchi K, Kahn BB, Masuzaki H, Kim JK, Lee SW, and Kim YB. Role of Rho-kinase in regulation of insulin action and glucose homeostasis. Cell Metab 2: 119-129, 2005.
42. Garg UC and Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83: 1774-1777, 1989.
43. Gauthier TW, Scalia R, Murohara T, Guo JP, and Lefer AM. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 15: 1652-1659, 1995.
44. Germershausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, and Alberts AW. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 158: 667-675, 1989.
45. Goldin A, Beckman JA, Schmidt AM, and Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114: 597-605, 2006.
46. Goldstein JL and Brown MS. Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
47. Goto H, Kosako H, Tanabe K, Yanagida M, Sakurai M, Amano M, Kaibuchi K, and Inagaki M. Phosphorylation of vimentin by Rho-associated kinase at a unique aminoterminal site that is specifically phosphorylated during cytokinesis. J Biol Chem 273: 11728-11736, 1998.
48. Hagerty L, Weitzel DH, Chambers J, Fortner CN, Brush MH, Loiselle D, Hosoya H, and Haystead TA. ROCK1 phosphorylates and activates zipper-interacting protein kinase. J Biol Chem 282: 4884-4893, 2007.
49. Hall A. Small GTP-binding proteins and the regulation of the actin cytoskeleton. Annu Rev Cell Biol 10: 31-54, 1994.
50. Hall A. Rho GTPases and the actin cytoskeleton. Science 279: 509-514, 1998.
51. Hara Y, Wakino S, Tanabe Y, Saito M, Tokuyama H, Washida N, Tatematsu S, Yoshioka K, Homma K, Hasegawa K, Minakuchi H, Fujimura K, Hosoya K, Hayashi K, Nakayama K, and Itoh H. Rho and Rho-kinase activity in adipocytes contributes to a vicious cycle in obesity that may involve mechanical stretch. Sci Signal 4: ra3, 2011.
52. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Kaibuchi K, and Takeshita A. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 94: 46-52, 2004.
53. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H, Kaibuchi K, and Takeshita A. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109: 2234-2239, 2004.
54. Heineke J and Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589-600, 2006.
55. Hengst L and Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 271: 1861-1864, 1996.
56. Hidaka T, Hata T, Soga J, Fujii Y, Idei N, Fujimura N, Kihara Y, Noma K, Liao JK, and Higashi Y. Increased leukocyte rho kinase (ROCK) activity and endothelial dysfunction in cigarette smokers. Hypertens Res 33: 354-359, 2010.
57. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, and Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93: 767-775, 2003.
58. Hill JA and Olson EN. Cardiac plasticity. N Engl J Med 358: 1370-1380, 2008.
59. Hirose A, Tanikawa T, Mori H, Okada Y, and Tanaka Y. Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway. FEBS Lett 584: 61-66, 2010.
60. Hofmann F, Feil R, Kleppisch T, and Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 86: 1-23, 2006.
61. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, and Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377: 239-242, 1995.
62. Hughes DA. Control of signal transduction and morphogenesis by Ras. Semin Cell Biol 6: 89-94, 1995.
63. Ignarro LJ, Buga GM, Wood KS, Byrns RE, and Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84: 9265-9269, 1987.
64. Ikegaki I, Hattori T, Yamaguchi T, Sasaki Y, Satoh SI, Asano T, and Shimokawa H. Involvement of Rho-kinase in vascular remodeling caused by long-term inhibition of nitric oxide synthesis in rats. Eur J Pharmacol 427: 69-75, 2001.
65. Istvan ES and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292: 1160-1164, 2001.
66. Iwasaki H, Okamoto R, Kato S, Konishi K, Mizutani H, Yamada N, IsakaN,Nakano T, and ItoM.High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis 196: 22-28, 2008.
67. Jakobisiak M, Bruno S, Skierski JS, and Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88: 3628-3632, 1991.
68. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, and Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 60: 875-881, 2012.
69. Kamari Y, Bitzur R, Cohen H, Shaish A, and Harats D. Should all diabetic patients be treated with a statin? Diabetes Care 32 Suppl 2: S378-S383, 2009.
70. Kanda T, Wakino S, Homma K, Yoshioka K, Tatematsu S, Hasegawa K, Takamatsu I, Sugano N, Hayashi K, and Saruta T. Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J 20: 169-171, 2006.
71. Kaneko T, Amano M, Maeda A, Goto H, Takahashi K, Ito M, and Kaibuchi K. Identification of calponin as a novel substrate of Rho-kinase. Biochem Biophys Res Commun 273: 110-116, 2000.
72. This reference has been deleted.
73. Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, Kitamoto S, Usui M, Kaibuchi K, Shimokawa H, and Takeshita A. Important role of Rhokinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39: 245-250, 2002.
74. Katsumata N, Shimokawa H, Seto M, Kozai T, Yamawaki T, Kuwata K, Egashira K, Ikegaki I, Asano T, Sasaki Y, and Takeshita A. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta. Circulation 96: 4357-4363, 1997.
75. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, and Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273: 245-248, 1996.
76. Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, Tagawa T, Shimokawa H, Takeshita A, and Sunagawa K. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 111: 2741-2747, 2005.
77. Kishore R, Qin G, Luedemann C, Bord E, Hanley A, Silver M, Gavin M, Yoon YS, Goukassian D, and Losordo DW. The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. J Clin Invest 115: 1785-1796, 2005.
78. Kitazawa T, Eto M, Woodsome TP, and Brautigan DL. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J Biol Chem 275: 9897-9900, 2000.
79. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333: 621-627, 1995.
80. Kobayashi N, Horinaka S, Mita S, Nakano S, Honda T, Yoshida K, Kobayashi T, and Matsuoka H. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 55: 757-767, 2002.
81. Kosmidou I, Moore JP, Weber M, and Searles CD. Statin treatment and 3¢ polyadenylation of eNOS mRNA. Arterioscler Thromb Vasc Biol 27: 2642-2649, 2007.
82. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010, 2000.
83. This reference has been deleted.
84. Langer HF and Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 99: 480-486, 2008.
85. Laufs U, Endres M, Stagliano N, Amin-Hanjani S, Chui DS, Yang SX, Simoncini T, Yamada M, Rabkin E, Allen PG, Huang PL, Bohm M, Schoen FJ, Moskowitz MA, and Liao JK. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 106: 15-24, 2000.
86. Laufs U, Fata VL, and Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxiamediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272: 31725-31729, 1997.
87. Laufs U, La Fata V, Plutzky J, and Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135, 1998.
88. Laufs U and Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998.
89. Laufs U, Marra D, Node K, and Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPaseinduced down-regulation of p27(Kip1). J Biol Chem 274: 21926-21931, 1999.
90. Lee DH, Shi J, Jeoung NH, Kim MS, Zabolotny JM, Lee SW, White MF, Wei L, and Kim YB. Targeted disruption of ROCK1 causes insulin resistance in vivo. J Biol Chem 284: 11776-11780, 2009.
91. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, and Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100: 178-184, 1999.
92. Li J, Jiang J, Yin H, Wang L, Tian R, Li H, Wang Z, Li D, Wang Y, Gui Y, Walsh MP, and Zheng XL. Atorvastatin inhibits myocardin expression in vascular smooth muscle cells. Hypertension 60: 145-153, 2012.
93. Li M, Liu Y, Dutt P, Fanburg BL, and Toksoz D. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Am J Physiol Lung Cell Mol Physiol 293: L463-L471, 2007.
94. Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, Tang L, Hla T, Zeng R, Li L, and Wu D. Regulation of PTEN by Rho small GTPases. Nat Cell Biol 7: 399-404, 2005.
95. Liao JK. Inhibition of Gi proteins by low density lipoprotein attenuates bradykinin-stimulated release of endothelial-derived nitric oxide. J Biol Chem 269: 12987-12992, 1994.
96. Libby P. Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
97. Libby P, Ridker PM, and Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
98. Lim MJ, Choi KJ, Ding Y, Kim JH, Kim BS, Kim YH, Lee J, Choe W, Kang I, Ha J, Yoon KS, and Kim SS. RhoA/Rho kinase blocks muscle differentiation via serine phosphorylation of insulin receptor substrate-1 and-2. Mol Endocrinol 21: 2282-2293, 2007.
99. Liu PY, Chen JH, Lin LJ, and Liao JK. Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol 49: 1619-1624, 2007.
100. Lohn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, Schaefer M, Linz W, Kohlmann M, Herbert JM, Janiak P, O'Connor SE, and Ruetten H. Pharmacological characterization of SAR407899, a novel rhokinase inhibitor. Hypertension 54: 676-683, 2009.
101. Loirand G and Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol 7: 637-647, 2010.
102. Mallat Z, Gojova A, Sauzeau V, Brun V, Silvestre JS, Esposito B, Merval R, Groux H, Loirand G, and Tedgui A. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 93: 884-888, 2003.
103. Maron DJ, Fazio S, and Linton MF. Current perspectives on statins. Circulation 101: 207-213, 2000.
104. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, and Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105: 1545-1547, 2002.
105. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, and Yang Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 22: 8467-8477, 2002.
106. Miyamoto S, Del Re DP, Xiang SY, Zhao X, Florholmen G, and Brown JH. Revisited and revised: is RhoA always a villain in cardiac pathophysiology? J Cardiovasc Transl Res 3: 330-343, 2010.
107. Morishige K, Shimokawa H, Eto Y, Hoshijima M, Kaibuchi K, and Takeshita A. In vivo gene transfer of dominantnegative rho-kinase induces regression of coronary arteriosclerosis in pigs. Ann N Y Acad Sci 947: 407-411, 2001.
108. Mueller BK, Mack H, and Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4: 387-398, 2005.
109. Munzel T and Gori T. Nitrate therapy and nitrate tolerance in patients with coronary artery disease. Curr Opin Pharmacol 13: 251-259, 2013.
110. Nakayama Y, Komuro R, Yamamoto A, Miyata Y, Tanaka M, Matsuda M, Fukuhara A, and Shimomura I. RhoA induces expression of inflammatory cytokine in adipocytes. Biochem Biophys Res Commun 379: 288-292, 2009.
111. Noguchi M, Hosoda K, Fujikura J, Fujimoto M, Iwakura H, Tomita T, Ishii T, Arai N, Hirata M, Ebihara K, Masuzaki H, Itoh H, Narumiya S, and Nakao K. Genetic and pharmacological inhibition of Rho-associated kinase II enhances adipogenesis. J Biol Chem 282: 29574-29583, 2007.
112. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, Liao JK, and Creager MA. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 99: 1426-1432, 2006.
113. Nohria A, Prsic A, Liu PY, Okamoto R, Creager MA, Selwyn A, Liao JK, and Ganz P. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205: 517-521, 2009.
114. Noma K, Goto C, Nishioka K, Jitsuiki D, Umemura T, Ueda K, Kimura M, Nakagawa K, Oshima T, Chayama K, Yoshizumi M, Liao JK, and Higashi Y. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol 49: 698-705, 2007.
115. Noma K, Higashi Y, Jitsuiki D, Hara K, Kimura M, Nakagawa K, Goto C, Oshima T, Yoshizumi M, and Chayama K. Smoking activates rho-kinase in smooth muscle cells of forearm vasculature in humans. Hypertension 41: 1102-1105, 2003.
116. Noma K, Oyama N, and Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 290: C661-C668, 2006.
117. Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, Okamoto R, Hiroi Y, Shimizu K, Luscinskas FW, Sun J, and Liao JK. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 118: 1632-1644, 2008.
118. O'Driscoll G, Green D, and Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95: 1126-1131, 1997.
119. Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S, and Mizuno K. Rho-associated kinase ROCK activates LIMkinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem 275: 3577-3582, 2000.
120. Okamoto R, Li Y, Noma K, Hiroi Y, Liu PY, Taniguchi M, Ito M, and Liao JK. FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J 27: 1439-1449, 2013.
121. Okon EB, Szado T, Laher I,McManus B, and van Breemen C. Augmented contractile response of vascular smooth muscle in a diabetic mouse model. J Vasc Res 40: 520-530, 2003.
122. Oshiro N, Fukata Y, and Kaibuchi K. Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J Biol Chem 273: 34663-34666, 1998.
123. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 21: 3-5, 2001.
124. Preiss D and Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol 22: 460-466, 2011.
125. Radomski MW, Rees DD, Dutra A, and Moncada S. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 107: 745-749, 1992.
126. Rekhter M, Chandrasekhar K, Gifford-Moore D, Huang XD, Rutherford P, Hanson J, and Kauffman R. Immunohistochemical analysis of target proteins of Rho-kinase in a mouse model of accelerated atherosclerosis. Exp Clin Cardiol 12: 169-174, 2007.
127. Riento K and Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4: 446-456, 2003.
128. Riento K, Totty N, Villalonga P, Garg R, Guasch R, and Ridley AJ. RhoE function is regulated by ROCK I-mediated phosphorylation. EMBO J 24: 1170-1180, 2005.
129. Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, Moskowitz MA, and Liao JK. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36: 2251-2257, 2005.
130. Rikitake Y and Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 111: 3261-3268, 2005.
131. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, and Liao JK. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1 +/-haploinsufficient mice. Circulation 112: 2959-2965, 2005.
132. Romero MJ, Iddings JA, Platt DH, Ali MI, Cederbaum SD, Stepp DW, Caldwell RB, and Caldwell RW. Diabetesinduced vascular dysfunction involves arginase I. Am J Physiol Heart Circ Physiol 302: H159-H166, 2012.
133. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, Caldwell RB, and Caldwell RW. Diabetesinduced coronary vascular dysfunction involves increased arginase activity. Circ Res 102: 95-102, 2008.
134. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
135. Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, Sanchez-Lopez E, Rodriguez-Vita J, Esteban V, Carvajal G, Plaza JJ, Egido J, and Ruiz-Ortega M. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 50: 377-383, 2007.
136. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009, 1996.
137. Sampson UK, Linton MF, and Fazio S. Are statins diabetogenic? Curr Opin Cardiol 26: 342-347, 2011.
138. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, and Makino N. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertensioninduced heart failure. J Mol Cell Cardiol 35: 59-70, 2003.
139. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, and Loirand G. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2 + sensitization of contraction in vascular smooth muscle. J Biol Chem 275: 21722-21729, 2000.
140. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88: 1102-1104, 2001.
141. Sawada N, Itoh H, Miyashita K, Tsujimoto H, Sone M, Yamahara K, Arany ZP, Hofmann F, and Nakao K. Cyclic GMP kinase and RhoA Ser188 phosphorylation integrate pro-and antifibrotic signals in blood vessels. Mol Cell Biol 29: 6018-6032, 2009.
142. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, Inoue M, Masatsugu K, Saito T, Fukunaga Y, Sakaguchi S, Arai H, Ohno N, Komeda M, and Nakao K. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101: 2030-2033, 2000.
143. Sawada N, Itoh H, Yamashita J, Doi K, Inoue M, Masatsugu K, Fukunaga Y, Sakaguchi S, Sone M, Yamahara K, Yurugi T, and Nakao K. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun 280: 798-805, 2001.
144. Seasholtz TM, Majumdar M, Kaplan DD, and Brown JH. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 84: 1186-1193, 1999.
145. Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, and Breard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol 3: 346-352, 2001.
146. This reference has been deleted.
147. Shao J, Welch WJ, Diprospero NA, and Diamond MI. Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol 28: 5196-5208, 2008.
148. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, and Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307, 1995.
149. Shi J, Zhang YW, Summers LJ, Dorn GW, 2nd, and Wei L. Disruption of ROCK1 gene attenuates cardiac dilation and improves contractile function in pathological cardiac hypertrophy. J Mol Cell Cardiol 44: 551-560, 2008.
150. Shi J, Zhang YW, Yang Y, Zhang L, and Wei L. ROCK1 plays an essential role in the transition from cardiac hypertrophy to failure in mice. J Mol Cell Cardiol 49: 819-828, 2010.
151. Shibuya M, Hirai S, Seto M, Satoh S, and Ohtomo E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 238: 31-39, 2005.
152. Shiga N, Hirano K, Hirano M, Nishimura J, Nawata H, and Kanaide H. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ Res 96: 1014-1021, 2005.
153. Shimizu K, Aikawa M, Takayama K, Libby P, and Mitchell RN. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 108: 2113-2120, 2003.
154. Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, Noda Y, Matsumura F, Taketo MM, and Narumiya S. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 168: 941-953, 2005.
155. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39: 319-327, 2002.
156. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T, Nakashima M, and Kato K. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 40: 751-761, 2002.
157. Shimokawa H, Morishige K, Miyata K, Kandabashi T, Eto Y, Ikegaki I, Asano T, Kaibuchi K, and Takeshita A. Longterm inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 51: 169-177, 2001.
158. Shimokawa H and Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 28: 296-302, 2007.
159. Shimokawa H and Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-1775, 2005.
160. Shirao S, Fujisawa H, Kudo A, Kurokawa T, Yoneda H, Kunitsugu I, Ogasawara K, Soma M, Kobayashi S, Ogawa A, and Suzuki M. Inhibitory effects of eicosapentaenoic acid on chronic cerebral vasospasm after subarachnoid hemorrhage: possible involvement of a sphingosylphosphorylcholine-rho-kinase pathway. Cerebrovasc Dis 26: 30-37, 2008.
161. Sordella R, Jiang W, Chen GC, Curto M, and Settleman J. Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell 113: 147-158, 2003.
162. Sowers JR and Lester MA. Diabetes and cardiovascular disease. Diabetes Care 22 Suppl 3: C14-C20, 1999.
163. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, and Witztum JL. Beyond cholesterol. Modifications of lowdensity lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924, 1989.
164. This reference has been deleted.
165. Sumi T, Matsumoto K, and Nakamura T. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J Biol Chem 276: 670-676, 2001.
166. Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, and Takakura K. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the postmarketing surveillance study. Neurol Med Chir (Tokyo) 48: 241-247; discussion 247-248, 2008.
167. Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A, Shimokawa H, and Takeshita A. Critical role of Rhokinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 21: 868-873, 2001.
168. Takemoto M, Sun J, Hiroki J, Shimokawa H, and Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106: 57-62, 2002.
169. a. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365-374, 1984.
170. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, and Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994, 1997.
171. Van Aelst L and D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 11: 2295-2322, 1997.
172. van Nieuw Amerongen GP, Vermeer MA, and van Hinsbergh VW. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 20: E127-E133, 2000.
173. Vemula S, Shi J, Hanneman P, Wei L, and Kapur R. ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood 115: 1785-1796, 2010.
174. Vogt A, Qian Y, McGuire TF, Hamilton AD, and Sebti SM. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 13: 1991-1999, 1996.
175. Wang CY, Liu PY, and Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14: 37-44, 2008.
176. Wang HW, Liu PY, Oyama N, Rikitake Y, Kitamoto S, Gitlin J, Liao JK, and Boisvert WA. Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/-mice. FASEB J 22: 3561-3570, 2008.
177. Ward Y, Yap SF, Ravichandran V, Matsumura F, Ito M, Spinelli B, and Kelly K. The GTP binding proteins Gem and Rad are negative regulators of the Rho-Rho kinase pathway. J Cell Biol 157: 291-302, 2002.
178. Weber M, Hagedorn CH, Harrison DG, and Searles CD. Laminar shear stress and 3¢ polyadenylation of eNOS mRNA. Circ Res 96: 1161-1168, 2005.
179. Werns SW, Walton JA, Hsia HH, Nabel EG, Sanz ML, and Pitt B. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 79: 287-291, 1989.
180. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P, and Liao JK. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 24: 1842-1847, 2004.
181. Yang Z, Kozai T, van der Loo B, Viswambharan H, Lachat M, Turina MI, Malinski T, and Luscher TF. HMGCoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 36: 1691-1697, 2000.
182. Yoneda A, Multhaupt HA, and Couchman JR. The Rho kinases I and II regulate different aspects of myosin II activity. J Cell Biol 170: 443-453, 2005.
183. Zhang YM, Bo J, Taffet GE, Chang J, Shi J, Reddy AK, Michael LH, Schneider MD, Entman ML, Schwartz RJ, and Wei L. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J 20: 916-925, 2006.
184. Zhou Q and Liao JK. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des 15: 3108-3115, 2009.
185. Zhou Q and Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 15: 467-478, 2009.
186. Zhou Q and Liao JK. Pleiotropic effects of statins.Basic research and clinical perspectives. Circ J 74: 818-826, 2010.
187. Zhou Q, Mei Y, Shoji T, Han X, Kaminski K, Oh GT, Ongusaha PP, Zhang K, Schmitt H, Moser M, Bode C, and Liao JK. Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis. Circulation 126: 2236-2247, 2012.